Idea Development Award – HT9425-23-DMDRP-IDA
- up to USD$350,000 over 2 years
- letters of intent due 2 August 2023
- Supports the development of innovative, high-impact ideas that advance the understanding of DMD and ultimately lead to improved outcomes.
- Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Therapies that will be efficacious across the lifespan, including infants, toddlers, and non- ambulatory individuals, are strongly encouraged.
- preliminary data required
- clinical trials not allowed
Translational Research Award – HT9425-23-DMDRP-TRA
- up to USD$1.25M over 3 years OR up to USD$1.35M over 3 years (Early-Career partnering PI option)
- letters of intent due 2 August 2023
- Supports advanced translational studies that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic.
- Research projects investigating therapies that will be efficacious across the lifespan, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged.
- Preliminary data required
- clinical trials allowed
Supporting documents
Duchenne Muscular Dystrophy Research Program Reference Table: 23dmdrpreftable
Idea Development Award: HT9425-FY23-DMDRP-IDA-GG
Translational Research Award: HT9425-FY23-DMDRP-TRA-GG
